Skip to main content
Erschienen in: Der Schmerz 2/2020

02.01.2020 | Cannabinoide | Übersichten

Cannabidiol bei Tumorerkrankungen

verfasst von: Rudolf Likar, Dr. Markus Köstenberger, Gerhard Nahler

Erschienen in: Der Schmerz | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Cannabis wurde bereits vor ca. 2500 Jahren bei Krebspatienten verwendet. Experimentelle Untersuchungen zeigten schon vor mehr als 40 Jahren eine tumorinhibierende Aktivität verschiedener Cannabinoide. In Anbetracht der Stellung von THC als Suchtgift kommt dem nichtpsychotomimetischen CBD eine besondere Bedeutung zu.

Fragestellung

Tumorwirksamkeit von reinem CBD in verschiedenen Tiermodellen sowie erste Ergebnisse (Fallberichte) an Patienten.

Material, Methode

Übersicht der Literatur zu Tierstudien und Fallberichte mit CBD

Ergebnisse

Präklinische Untersuchungen insbesondere während der letzten Jahre, darunter an zahlreichen Tumormodellen am Tier, weisen unisono auf eine therapeutische Wirksamkeit von CBD hin. In vereinzelt durchgeführten Kombinationsstudien zeigten sich in der Regel synergistische Effekte. Darüber hinaus kann CBD möglicherweise in der palliativmedizinischen Versorgung von Patienten insbesondere bei Symptomen wie Schmerzen, Schlaflosigkeit, Angstzuständen und Depression eine Rolle spielen. Weitergehende Humanstudien wären wünschenswert.
Literatur
2.
Zurück zum Zitat Armstrong JL, Hill DS, McKee CS, Hernandez-Tiedra S, Lorente M, Lopez-Valero I et al (2015) Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death. J Invest Dermatol 135(6):1629–1637PubMedCrossRef Armstrong JL, Hill DS, McKee CS, Hernandez-Tiedra S, Lorente M, Lopez-Valero I et al (2015) Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death. J Invest Dermatol 135(6):1629–1637PubMedCrossRef
3.
Zurück zum Zitat Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F et al (2012) Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med 90(8):925–934PubMedCrossRef Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F et al (2012) Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med 90(8):925–934PubMedCrossRef
6.
Zurück zum Zitat Casey SL, Atwal N, Vaughan CW (2017) Cannabis constituent synergy in a mouse neuropathic pain model. Pain 158(12):2452–2460PubMedCrossRef Casey SL, Atwal N, Vaughan CW (2017) Cannabis constituent synergy in a mouse neuropathic pain model. Pain 158(12):2452–2460PubMedCrossRef
8.
Zurück zum Zitat De Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M et al (2019) Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain 160(1):136–150PubMedCrossRef De Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M et al (2019) Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain 160(1):136–150PubMedCrossRef
9.
Zurück zum Zitat De Petrocellis L, Ligresti A, Schiano Moriello A, Iapelli M, Verde R, Stott CG et al (2013) Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol 168:79–102PubMedPubMedCentralCrossRef De Petrocellis L, Ligresti A, Schiano Moriello A, Iapelli M, Verde R, Stott CG et al (2013) Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol 168:79–102PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H et al (2015) Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of cannabidiol in breast cancer. Mol Oncol 9:906–919PubMedPubMedCentralCrossRef Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H et al (2015) Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of cannabidiol in breast cancer. Mol Oncol 9:906–919PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling CE, Arifin SA et al (2018) GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene 37(49):6368–6382PubMedCrossRef Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling CE, Arifin SA et al (2018) GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene 37(49):6368–6382PubMedCrossRef
12.
Zurück zum Zitat Fisher Z, Golan H, Schiby G, PriChen S, Smoum R, Moshe I et al (2016) In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Curr Oncol 23(S2):S15–S22PubMedPubMedCentralCrossRef Fisher Z, Golan H, Schiby G, PriChen S, Smoum R, Moshe I et al (2016) In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Curr Oncol 23(S2):S15–S22PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Fouad AA, Albuali WH, Al-Mulhim AS, Jresat I (2013) Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity. Environ Toxicol Pharmacol 36(2):347–357PubMedCrossRef Fouad AA, Albuali WH, Al-Mulhim AS, Jresat I (2013) Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity. Environ Toxicol Pharmacol 36(2):347–357PubMedCrossRef
17.
Zurück zum Zitat Harris H, Radwan M, Gul W, ElSohly M, Sufka K (2018) Effects of cannabidiol and a novel cannabidiol analog against tactile allodynia in a murine model of cisplatin-induced neuropathy; synergistic effects of sub-analgesic doses of morphine. Med Cannabis Cannabinoids 1:54–59CrossRef Harris H, Radwan M, Gul W, ElSohly M, Sufka K (2018) Effects of cannabidiol and a novel cannabidiol analog against tactile allodynia in a murine model of cisplatin-induced neuropathy; synergistic effects of sub-analgesic doses of morphine. Med Cannabis Cannabinoids 1:54–59CrossRef
18.
Zurück zum Zitat Hay GL, Baracz SJ, Everett NA, Roberts J, Costa PA, Arnold JC et al (2018) Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats. J Psychopharmacol 32(12):1369–1378PubMedCrossRef Hay GL, Baracz SJ, Everett NA, Roberts J, Costa PA, Arnold JC et al (2018) Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats. J Psychopharmacol 32(12):1369–1378PubMedCrossRef
19.
Zurück zum Zitat Katsidoni V, Anagnostou I, Panagis G (2013) Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5‑HT 1A receptors in the dorsal raphe nucleus. Addict Biol 18:286–296PubMedCrossRef Katsidoni V, Anagnostou I, Panagis G (2013) Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5‑HT 1A receptors in the dorsal raphe nucleus. Addict Biol 18:286–296PubMedCrossRef
20.
Zurück zum Zitat Kenyon JN, Fuller RJ, Lewis TJ (2018) Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. Anticancer Res 38:5831–5835PubMedCrossRef Kenyon JN, Fuller RJ, Lewis TJ (2018) Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. Anticancer Res 38:5831–5835PubMedCrossRef
21.
Zurück zum Zitat King KM, Myers AM, Soroka-Monzo AJ, Tuma RF, Tallarida RJ, Walker EA et al (2017) Single and combined effects of ∆9-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. Br J Pharmacol 174(17):2832–2841PubMedPubMedCentralCrossRef King KM, Myers AM, Soroka-Monzo AJ, Tuma RF, Tallarida RJ, Walker EA et al (2017) Single and combined effects of ∆9-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. Br J Pharmacol 174(17):2832–2841PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L et al (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318(3):1375–1387PubMedCrossRef Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L et al (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318(3):1375–1387PubMedCrossRef
24.
Zurück zum Zitat Likar R, Koestenberger M, Stultschnig M, Nahler G (2019) Concomitant treatment of malignant brain tumours with CBD—a case series and review of the literature. Anticancer Res 39:5797–5801PubMedCrossRef Likar R, Koestenberger M, Stultschnig M, Nahler G (2019) Concomitant treatment of malignant brain tumours with CBD—a case series and review of the literature. Anticancer Res 39:5797–5801PubMedCrossRef
25.
Zurück zum Zitat Likar R, Nahler G (2017) The use of cannabis in supportive care and treatment of brain tumor. Neurooncol Pract 4(3):151–160PubMedPubMedCentral Likar R, Nahler G (2017) The use of cannabis in supportive care and treatment of brain tumor. Neurooncol Pract 4(3):151–160PubMedPubMedCentral
26.
Zurück zum Zitat Likar R (2016) Cannabidiol: Schmerzreduktion bei therapieresistenten Fällen Likar R (2016) Cannabidiol: Schmerzreduktion bei therapieresistenten Fällen
27.
Zurück zum Zitat Linge R, Jimenez-Sanchez L, Campa L, Pilar-Cuellar F, Vidal R, Pazos A et al (2016) Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5‑HT/glutamate neurotransmission: role of 5‑HT1A receptors. Neuropharmacology 103:16–26PubMedCrossRef Linge R, Jimenez-Sanchez L, Campa L, Pilar-Cuellar F, Vidal R, Pazos A et al (2016) Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5‑HT/glutamate neurotransmission: role of 5‑HT1A receptors. Neuropharmacology 103:16–26PubMedCrossRef
28.
Zurück zum Zitat Lukhele ST, Motadi LR (2016) Cannabidiol rather than cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells. BMC Complement Altern Med 16(1):335PubMedPubMedCentralCrossRef Lukhele ST, Motadi LR (2016) Cannabidiol rather than cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells. BMC Complement Altern Med 16(1):335PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Massi P, Solinas M, Cinquina V, Parolaro D (2013) Cannabidiol as potential anticancer drug. Br J Clin Pharmacol 75(2):303–312PubMedCrossRef Massi P, Solinas M, Cinquina V, Parolaro D (2013) Cannabidiol as potential anticancer drug. Br J Clin Pharmacol 75(2):303–312PubMedCrossRef
30.
Zurück zum Zitat Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E et al (2008) 5‑Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 104:1091–1100PubMedCrossRef Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E et al (2008) 5‑Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 104:1091–1100PubMedCrossRef
31.
Zurück zum Zitat Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D (2004) Antitumor effects of cannabidiol, a non-psychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308(3):838–845PubMedCrossRef Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D (2004) Antitumor effects of cannabidiol, a non-psychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308(3):838–845PubMedCrossRef
32.
Zurück zum Zitat Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA (1975) Antineoplastic activity of cannabinoids. J Natl Cancer Inst 55(3):597–602PubMedCrossRef Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA (1975) Antineoplastic activity of cannabinoids. J Natl Cancer Inst 55(3):597–602PubMedCrossRef
33.
Zurück zum Zitat Pan H, Mukhopadhyay P, Rajesh M, Patel V, Mukhopadhyay B, Gao B et al (2009) Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation and cell death. J Pharmacol Exp Ther 328(3):708–714PubMedCrossRef Pan H, Mukhopadhyay P, Rajesh M, Patel V, Mukhopadhyay B, Gao B et al (2009) Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation and cell death. J Pharmacol Exp Ther 328(3):708–714PubMedCrossRef
34.
Zurück zum Zitat Ramer R, Bublitz K, Freimuth N, Merkord J, Rohde H, Haustein M et al (2012) Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule‑1. Faseb J 26(4):1535–1548PubMedCrossRef Ramer R, Bublitz K, Freimuth N, Merkord J, Rohde H, Haustein M et al (2012) Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule‑1. Faseb J 26(4):1535–1548PubMedCrossRef
35.
Zurück zum Zitat Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ et al (2012) Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5‑HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 165(8):2620–2634PubMedPubMedCentralCrossRef Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ et al (2012) Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5‑HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 165(8):2620–2634PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Romano B (2014) Non-psychotropic phytocannabinoids in intestinal inflammation and colon cancer Romano B (2014) Non-psychotropic phytocannabinoids in intestinal inflammation and colon cancer
37.
Zurück zum Zitat Scott KA, Dalgleish AG, Liu WM (2014) The combination of cannabidiol and ∆9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther 13(12):2955–2967PubMedCrossRef Scott KA, Dalgleish AG, Liu WM (2014) The combination of cannabidiol and ∆9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther 13(12):2955–2967PubMedCrossRef
38.
Zurück zum Zitat Shannon S, Lewis N, Lee H, Hughes S (2019) Cannabidiol in anxiety and sleep: a large case series. Perm J 23:18–41 Shannon S, Lewis N, Lee H, Hughes S (2019) Cannabidiol in anxiety and sleep: a large case series. Perm J 23:18–41
39.
Zurück zum Zitat Sharafi G, He H, Nikfarjam M (2019) Potential use of cannabinoids for the treatment of pancreatic cancer. J Pancreat Cancer 5(1):1–7PubMedPubMedCentralCrossRef Sharafi G, He H, Nikfarjam M (2019) Potential use of cannabinoids for the treatment of pancreatic cancer. J Pancreat Cancer 5(1):1–7PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Simmerman E, Qin X, Yu JC, Baban B (2019) Cannabinoids as a potential new and novel treatment for melanoma: a pilot study in a murine model. J Surg Res 235:210–215PubMedCrossRef Simmerman E, Qin X, Yu JC, Baban B (2019) Cannabinoids as a potential new and novel treatment for melanoma: a pilot study in a murine model. J Surg Res 235:210–215PubMedCrossRef
42.
Zurück zum Zitat Soroceanu L, Murase R, Limbad C, Singer E, Allison J, Adrados I et al (2013) Id‑1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res 73(5):1559–1569PubMedCrossRef Soroceanu L, Murase R, Limbad C, Singer E, Allison J, Adrados I et al (2013) Id‑1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res 73(5):1559–1569PubMedCrossRef
43.
Zurück zum Zitat Sulé-Suso J, Watson NA, van Pittius DG, Jegannathen A (2019) Striking lung cancer response to self-administration of cannabidiol: a case report and literature review. SAGE Open Med Case Rep 7:1–4 Sulé-Suso J, Watson NA, van Pittius DG, Jegannathen A (2019) Striking lung cancer response to self-administration of cannabidiol: a case report and literature review. SAGE Open Med Case Rep 7:1–4
44.
Zurück zum Zitat Torres S, Lorente M, Rodriguez-Fornes F, Hernandez-Tiedra S, Salazar M, Garcia-Taboada E et al (2011) A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10(1):90–103PubMedCrossRef Torres S, Lorente M, Rodriguez-Fornes F, Hernandez-Tiedra S, Salazar M, Garcia-Taboada E et al (2011) A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10(1):90–103PubMedCrossRef
45.
Zurück zum Zitat Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I (2015) Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience. J Pain Symptom Manage 49(2):223–230PubMedCrossRef Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I (2015) Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience. J Pain Symptom Manage 49(2):223–230PubMedCrossRef
46.
Zurück zum Zitat Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA (2014) Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5‑HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol 171:636–645PubMedPubMedCentralCrossRef Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA (2014) Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5‑HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol 171:636–645PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Xu C, Chang T, Du Y, Yu C, Tan X, Li X (2019) Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model. Environ Toxicol Pharmacol 70:103202PubMedCrossRef Xu C, Chang T, Du Y, Yu C, Tan X, Li X (2019) Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model. Environ Toxicol Pharmacol 70:103202PubMedCrossRef
Metadaten
Titel
Cannabidiol bei Tumorerkrankungen
verfasst von
Rudolf Likar
Dr. Markus Köstenberger
Gerhard Nahler
Publikationsdatum
02.01.2020
Verlag
Springer Medizin
Schlagwörter
Cannabinoide
Kraniotomie
Erschienen in
Der Schmerz / Ausgabe 2/2020
Print ISSN: 0932-433X
Elektronische ISSN: 1432-2129
DOI
https://doi.org/10.1007/s00482-019-00438-9

Weitere Artikel der Ausgabe 2/2020

Der Schmerz 2/2020 Zur Ausgabe

President‘s Corner (Mitteilungen der SPS)

President‘s Corner (Mitteilungen der SPS)

President´s Corner (Mitteilungen der Deutschen Schmerzgesellschaft e.V.)

Mitteilungen der Deutschen Schmerzgesellschaft e.V.

Editorial

Cannabidiol

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.